Jazz Pharmaceuticals has agreed to pay $145 million to resolve antitrust litigation alleging Jazz entered into an unlawful agreement with Hikma Pharmaceuticals to prevent or delay competition from less expensive generic versions of Jazz’s popular narcolepsy drug Xyrem®. In connection with the settlement, which the Court must approve, Jazz has denied any wrongdoing.The case against Hikma Pharmaceuticals continues. That is scheduled to begin on May 19, 2025. Michael M. Buchman of Motley Rice serves as one of two co-lead counsel. Our antitrust litigation experienceTo promote the maintenance of a free and competitive global economy, our antitrust team seeks private enforcement actions against powerful and well-funded corporations. Our antitrust lawyers have litigated numerous cases involving a variety of industries and trade practices. For more on this and other antitrust matters, contact Motley Rice by email.